Sugi Predict

Sugi Predict / Compounds / SCHEMBL1759007

SCHEMBL1759007

SCHEMBL1759007

Cc1ccn2cc(C(=O)O)nc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.67
▸ POLB P06746 3/20 0.67
▸ ALDH1A1 P00352 6/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ PTGS1 P23219 1/20 0.58
▸ PTGS2 P35354 1/20 0.58
▸ NPC1 O15118 7/20 0.56
▸ RAB9A P51151 6/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ TP53 P04637 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ MAPT P10636 1/20 0.52
▸ HSD17B10 Q99714 2/20 0.50
▸ LMNA P02545 1/20 0.49
▸ GAA P10253 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ METTL3 Q86U44 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324585 0.87 KDM4E (0.67) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL30900623 0.85 KDM4E (0.65) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL4225329 0.83 KDM4E (0.59) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL17265004 0.83 KDM4E (0.62) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL17321405 0.83 KDM4E (0.62) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL31295448 0.81 KDM4E (0.64) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL9753536 0.81 PTGS1 (0.60) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL4348612 0.81 PTGS1 (0.60) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL22129486 0.81 PTGS1 (0.55) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL20250823 0.80 KDM4E (0.59) KDM4EPOLBALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310356-B1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME LUNDBECK & CO AS H (DK) 2013-08-14 — — EP claimed
JP-2011529057-A — — 2011-12-01 — — JP claimed
WO-2010011570-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 — — WO claimed
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 — — US claimed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
CN-120058672-A Halogenated pyridylcarboxylic acid ester derivative and application thereof 贵州医科大学 2025-05-30 — — CN disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 — — CN disclosed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 — — EP disclosed
CN-109641854-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-02-03 — — CN disclosed
US-11370758-B2 IDO-TDO dual inhibitor and related methods of use CMG PHARMACEUTICAL CO., LTD. (KR) 2022-06-28 — — US disclosed
US-11370758-B2 IDO-TDO dual inhibitor and related methods of use CMG PHARMACEUTICAL CO., LTD. (KR) 2022-06-28 — — US disclosed
WO-2011114271-A1 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR PFIZER INC. (US) 2011-09-22 — — WO disclosed
WO-2011058473-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 — — WO disclosed
WO-2011058474-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 — — WO disclosed
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC 2011-05-12 — — US disclosed
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 — — US disclosed
EP-0370381-B1 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1995-05-10 — — EP disclosed
US-4988698-A Cardiovascular disorders, hypotensive agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-29 — — US disclosed
EP-0370381-A2 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1385/4885POLB 1847/4885ALDH1A1 164/4885
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME QDPR, ADM2, PDE3B KDM4E 2749/4885POLB 4668/4885ALDH1A1 105/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 KDM4E 4646/4885POLB 1764/4885ALDH1A1 3433/4885
US-11370758-B2 IDO-TDO dual inhibitor and related methods of use IDO1, IDO2, TDO2 KDM4E 910/4885POLB 3553/4885ALDH1A1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.